Our company is backed by an advisory committee composed of professionals from the pharma sector with various years of experience in product and business development. They act at strategic level and advise the company in its long term activities.
Lluís Gómez, PhD
Scientific Director, Draconis Pharma
Dr. Gómez is currently Scientific Director at Draconis Pharma. He previously trained his expertise in drug development as project leader in J. Uriach & Cia. since year 1983 to 2000. During these years, he developed several preclinical projects related with different circulatory system responses. Later on, he was appointed as Head of Screening for the same company, being focused on the level of in vitro, in vivo and ADME/PK studies. In his current position in Draconis, he is still a scientific model in the field of in vitro, in vivo and ADMET screening.
Muddasar Farooq, PhD
CEO, Kirklees Biosciences
Dr. Farooq is already starting his own biotecnology commercial endeavour with Kirklees Biosciences. He has a long track recording of ADME and Cancer research experience. His expertise in drug discovery is a major asset for Kirklees, and was trained first in GlaxoSmithKline, Ferring Pharmaceuticals and finally in Cancer Research Technology for almost ten years. He exhibits a deep knowledge in the DMPK area, as well as in bioanalysis and method development.
Francesc Mitjans, PhD
CSO, Lykera Biomed
Dr. Mitjans is currently director of the Biomed Division of Leitat Technological Center (2008), where he steers the activities of the division. He is also Chief Scientific Officer at Lykera Biomed (2011), a biotech company dealing with innovative therapeutic and diagnostic oncology projects. He has over 15 years of experience in the pharmaceutical industry as Department Head at Merck-Serono, leading projects for preclinical and clinical development of new drugs and specially monoclonal antibodies in the area of tumor angiogenesis, tumor progression and metastasis.
Sandy is one of the co-founders of ADMEcell, a San Francisco based biotechnology company developing and marketing innovating Ready-to-Use Kits to assist and stream line drug development especially in the DMPK area. ADMEcell is Readycell’s exclusive partner in the United States. Sandy has over 25 years business and marketing experience in the in-vitro assay field between the diagnostic and drug development industries. Previously, Sandy was the founder of BiosPacific, an antibody manufacturer and supplier to the diagnostic industry. Biospacific pioneered antibodies to Troponin I for early detection of heart attacks. R & D Systems, a USA based company, acquired BiosPacific in 2005.
Josep Oriol Nicolas, PhD
CEO, Nostrum Biodiscovery
Dr. Nicolas is currently CEO of Nostrum Biodiscovery, a leading bioinformatic company focused in drug discovery. Oriol was previously involved as a Manager and CEO of ReadyCell several years. He started his career in Almirall, holds a PhD and MBA of Pharmaceutical industry. Also dedicated several years to international technology transfer management and technology brokerage in a strategic consultancy firm.